DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Graves’ Disease Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Graves’ Disease, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Graves’ Disease Market
The Graves’ Disease market size in the 7MM is expected to increase significantly during the forecast period from 2026 to 2036.
The Graves’ Disease market size in the 7MM was approximately USD 5 billion in 2025 and is projected to reach nearly USD 17.6 billion by 2036.
The United States accounted for the largest Graves’ Disease market size in 2025, contributing nearly 70% of the total market compared with EU4, the United Kingdom, and Japan.
In 2025, there were approximately 7.2 million prevalent cases of Graves’ Disease across the 7MM.
Among the 7MM, the United States accounted for the highest prevalence of Graves’ Disease, while Japan represented the lowest prevalence.
According to DelveInsight estimates, approximately 1.84 million diagnosed prevalent cases of Graves’ Disease were reported in the United States in 2025.
In 2025, Graves’ Ophthalmopathy represented the largest disease manifestation in the United States, accounting for approximately 608,500 cases.
Among the EU4 and the United Kingdom, Germany accounted for the highest diagnosed prevalent cases of Graves’ Disease in 2025, while Spain recorded the lowest.
In Japan, gender-specific diagnosed prevalent cases of Graves’ Disease were approximately 80,700 among males and 322,700 among females in 2025.
Leading Graves’ Disease companies, including Viridian Therapeutics, Immunovant, Biohaven, Tourmaline Bio, Hoffmann-La Roche, ACELYRIN, Lassen Therapeutics, Ollin Biosciences, Kriya Therapeutics, Crinetics Pharmaceuticals, and others, are actively developing innovative therapies to address the significant unmet need in the market.
Promising Graves’ Disease therapies in development include Veligrotug (VRDN-001), VRDN-003, Batoclimab (IMVT-1401), IMVT-1402, ENSPRYNG (Satralizumab), Lonigutamab, LASN01, Pacibekitug (TOUR006), BHV-1300, OLN102, and others.
Keen to know more about the market? Request our sample page. https://www.delveinsight.com/sample-request/graves-disease-market
Key Factors Driving the Graves’ Disease Market
The increasing prevalence of autoimmune thyroid disorders and growing awareness among healthcare professionals and patients are contributing to improved diagnosis and treatment rates.
The lack of approved disease-modifying therapies for Graves’ Disease and Graves’ Orbitopathy continues to create a substantial unmet need, encouraging investment in innovative treatment approaches.
Advances in immunology, biologics, and precision medicine are accelerating the development of targeted therapies aimed at addressing the underlying autoimmune mechanisms of the disease.
The growing adoption of advanced diagnostic technologies and biomarker-based treatment approaches is expected to improve patient outcomes and support long-term market growth.
Graves’ Disease Competitive Landscape
The Graves’ Disease pipeline is rapidly evolving, with several companies developing innovative therapies targeting distinct immune pathways. Key pipeline assets include Veligrotug (VRDN-001) and VRDN-003 from Viridian Therapeutics, Batoclimab and IMVT-1402 from Immunovant, ENSPRYNG from Hoffmann-La Roche, Lonigutamab from ACELYRIN, Pacibekitug from Tourmaline Bio, LASN01 from Lassen Therapeutics, BHV-1300 from Biohaven, and OLN102 from Ollin Biosciences.
These therapies utilize diverse mechanisms of action, including IGF-1R inhibition, FcRn inhibition, IL-6 receptor blockade, anti-IL-11 receptor targeting, and IgG degradation. Their anticipated launches are expected to reshape the treatment paradigm and address the substantial unmet needs associated with Graves’ Disease and Thyroid Eye Disease (TED).
Discover more about therapies set to grab major Graves’ Disease market share.
Recent Developments in the Graves’ Disease Market
In January 2026, Viridian Therapeutics announced that the PDUFA target date for Veligrotug is June 30, 2026, for the treatment of Thyroid Eye Disease.
In December 2025, Argenx discontinued the Phase III UplighTED studies evaluating subcutaneous efgartigimod in adults with active, moderate-to-severe Thyroid Eye Disease associated with Graves’ Disease and Hashimoto’s thyroiditis.
In November 2025, Biohaven announced strategic portfolio optimization measures prioritizing BHV-1300 for Graves’ Disease.
In September 2025, Immunovant presented six-month off-treatment data for uncontrolled Graves’ Disease patients treated with Batoclimab at the Annual Meeting of the American Thyroid Association.
In June 2025, TEPEZZA received marketing authorization in the European Union for the treatment of moderate-to-severe Thyroid Eye Disease in adults.
What is Graves’ Disease?
Graves’ Disease is an autoimmune disorder and the most common cause of hyperthyroidism. It occurs when the immune system produces antibodies that stimulate the thyroid gland, leading to excessive thyroid hormone production. Common symptoms include nervousness, irritability, insomnia, tremors, sweating, muscle weakness, and goiter. The disease may also result in extrathyroidal manifestations such as Graves’ Ophthalmopathy, Graves’ Dermopathy, and Graves’ Acropachy. Current treatment options include anti-thyroid medications, radioactive iodine therapy, and thyroidectomy, while emerging targeted therapies aim to address the underlying autoimmune mechanisms of the disease.
Graves’ Disease Epidemiology Segmentation
The Graves’ Disease epidemiology section provides insights into the historical and current patient pool and forecasted trends across the seven major markets. The report offers epidemiological analysis for the study period 2022–2036 segmented into:
Total Prevalent Cases of Graves’ Disease
Total Diagnosed Prevalent Cases of Graves’ Disease
Gender-specific Cases of Graves’ Disease
Graves’ Disease Cases by Manifestations
Country-specific Patient Population
Thyroid Eye Disease-related Patient Population
Scope of the Graves’ Disease Market Report
Therapeutic Assessment: Graves’ Disease current marketed and emerging therapies
Graves’ Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Drugs and Market Outlook
Key Companies: Viridian Therapeutics, Immunovant, Biohaven, Tourmaline Bio, Hoffmann-La Roche, ACELYRIN, Lassen Therapeutics, Ollin Biosciences, Kriya Therapeutics, Crinetics Pharmaceuticals, and others
Key Therapies: TEPEZZA, Veligrotug (VRDN-001), VRDN-003, Batoclimab, IMVT-1402, ENSPRYNG, Lonigutamab, LASN01, Pacibekitug, BHV-1300, OLN102, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
Unmet Needs, KOL Views, Analyst Views, Market Access, and Reimbursement Assessment
To know more about Graves’ Disease companies working in the treatment market, visit Graves’ Disease Clinical Trials and Therapeutic Assessment.
Table of Contents
Graves’ Disease Market Report Introduction
Executive Summary for Graves’ Disease
SWOT Analysis of Graves’ Disease
Graves’ Disease Patient Share (%) Overview at a Glance
Graves’ Disease Market Overview at a Glance
Graves’ Disease Background and Overview
Graves’ Disease Epidemiology and Patient Population
Country-Specific Patient Population of Graves’ Disease
Graves’ Disease Current Treatment and Medical Practices
Graves’ Disease Unmet Needs
Graves’ Disease Emerging Therapies
Graves’ Disease Market Outlook
Country-Wise Graves’ Disease Market Analysis (2022–2036)
Graves’ Disease Market Access and Reimbursement
Graves’ Disease Market Drivers
Graves’ Disease Market Barriers
Graves’ Disease Appendix
Graves’ Disease Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
